Depo-Provera meningioma settlement values are projected over a broad range — commonly discussed from roughly $25,000 for smaller monitored tumors to $250,000 to $1,000,000 or more for meningiomas requiring craniotomy with lasting neurological deficits. This Depo-Provera meningioma settlement calculator estimates a payout from your injury-severity tier, medical bills, lost wages, and a pain-and-suffering multiplier. The cases are consolidated in the federal Depo-Provera multidistrict litigation (MDL 3140) before the U.S. District Court for the Northern District of Florida. Use the calculator, then read how the science, the MDL, and damages combine.
Depo-Provera (medroxyprogesterone acetate) is a long-acting injectable contraceptive. Plaintiffs allege that long-term use significantly increases the risk of developing intracranial meningiomas — usually benign but potentially serious brain tumors — and that the manufacturer (Pfizer) failed to warn U.S. patients, even though European regulators required meningioma warnings. The litigation accelerated after a March 2024 study in the BMJ reported an elevated meningioma risk with prolonged use.
Because the Depo-Provera litigation is new and brain-tumor cases remain in pretrial MDL proceedings with no jury trials yet, there is no established average payout. Projected values combine an injury-severity tier with conventional damage math. The calculator follows this approach:
Depo-Provera Estimate = Injury-Severity-Tier Anchor + Economic Damages (medical + lost wages) + Pain & Suffering (medical × multiplier)
A meningioma requiring craniotomy (brain surgery) that leaves lasting neurological deficits anchors the top tier. A resected tumor with residual symptoms anchors the middle tier. A treated or monitored tumor, and a smaller tumor under surveillance, anchor lower tiers. Imaging, neurosurgical records, and proof of long-term Depo-Provera use are central.
| Tier | Injury Profile | Projected Range |
|---|---|---|
| Tier 1 | Meningioma + craniotomy with lasting deficits | ~$250,000 – $1,000,000+ |
| Tier 2 | Meningioma resected, residual symptoms | ~$100,000 – $400,000 |
| Tier 3 | Meningioma treated/monitored | ~$50,000 – $200,000 |
| Tier 4 | Smaller tumor, surveillance | ~$25,000 – $100,000 |
The litigation's scientific anchor is a March 2024 study published in the BMJ, which found that prolonged use of medroxyprogesterone acetate (the active ingredient in Depo-Provera) was associated with a significantly increased risk of intracranial meningioma. Plaintiffs note that the European and Canadian labels carried meningioma warnings while the U.S. label allegedly did not, supporting a failure-to-warn theory. In February 2025, the Judicial Panel on Multidistrict Litigation centralized the cases into MDL 3140 before Judge M. Casey Rodgers in the Northern District of Florida. As of 2026 the litigation was in early pretrial stages — gathering plaintiff records, litigating general causation, and preparing for bellwether selection — so outcomes remain uncertain.
Suppose a long-term Depo-Provera user who developed a meningioma requiring craniotomy and was left with partial vision loss (Tier 1) has $150,000 in medical bills, $60,000 in lost wages, and a pain-and-suffering multiplier of 3.5. The calculator computes economic damages of $210,000 and pain-and-suffering of $525,000 (medical × 3.5), for a formula value of $735,000 within the Tier 1 band, with a likely range near $404,250 to $1,102,500. Because causation is unsettled, the actual outcome is uncertain. A Tier 3 case of a monitored tumor with $40,000 in medical bills and a multiplier of 2 would land near that tier's anchor.
Under IRS Publication 4345, compensatory damages for a personal physical injury or sickness — including a brain tumor and its treatment — are generally excluded from taxable income. Interest and punitive damages are taxable, and amounts allocated to non-physical claims may be treated differently. Confirm your specific tax treatment with a qualified professional.
A Depo-Provera claim starts with imaging and neurosurgical records documenting the meningioma and any surgery, plus medical and pharmacy records proving long-term use. The case is filed into MDL 3140 in the Northern District of Florida, joining others for coordinated discovery. Because the litigation is new — centralized in February 2025 with no jury trials yet — the court must first develop the general-causation evidence built on the March 2024 BMJ study, then prepare bellwether trials. Any settlement framework would follow favorable rulings and verdicts, with claims tiered by tumor severity and treatment. Given how early the litigation is, Depo-Provera claimants should expect a multi-year, uncertain timeline.
Depo-Provera cases are handled on contingency, with the attorney earning a percentage of any recovery (commonly 33% to 40%) plus case costs, which include the expert neuro-oncology and epidemiology testimony needed on causation. Health insurers, Medicare, or Medicaid may assert liens for brain-tumor treatment, repaid from the settlement but often negotiable. This calculator estimates a gross value; the net is what remains after fees, costs, and liens. On a $400,000 gross settlement with a 40% fee, $18,000 in costs, and a $22,000 negotiated lien, the net would be roughly $200,000. Ask your attorney for a written breakdown.
The central uncertainty is general causation: the litigation rests on the 2024 BMJ findings, and defendants will contest whether the science proves Depo-Provera causes meningioma. Short-duration use weakens the causal link, since risk was tied to prolonged use. A strong alternative explanation for the tumor, or sparse records of drug use, can lower value. Because the litigation is so new and no settlement matrix existed as of 2026, all figures are projections. Do not stop a prescribed contraceptive over the lawsuit; discuss alternatives with your doctor if you have concerns.
This Depo-Provera meningioma settlement calculator is intended for women who used Depo-Provera (or generic medroxyprogesterone acetate) as a contraceptive — typically for an extended period — and were later diagnosed with an intracranial meningioma. It is most relevant to those whose tumor required craniotomy or other surgery and who were left with neurological deficits such as vision loss, seizures, or cognitive impairment, and to families pursuing claims after a catastrophic outcome. Because the litigation is new and rests on 2024 epidemiology, the tool is best treated as an educational illustration. Women with concerns should not stop a prescribed contraceptive over the lawsuit but should discuss alternatives with their doctor and seek a case review.
The essentials of Depo-Provera claims are these. Tumor severity and treatment set the tier, with craniotomy and lasting deficits anchoring the top. Long-term use strengthens causation, because the 2024 BMJ study tied the elevated meningioma risk to prolonged use. General causation will be heavily contested, and the litigation — centralized as MDL 3140 in Florida in February 2025 — had no jury trials or settlement matrix as of 2026, so all figures are projections. The gross estimate is reduced by attorney fees, costs, and liens. And because the U.S. label allegedly lacked the meningioma warning that European labels carried, failure-to-warn is central. Use the calculator for orientation and let counsel evaluate your records.
This is emerging litigation with no jury trials yet, so figures are projections. Estimates span roughly $25,000 for smaller monitored tumors to $250,000-$1,000,000 or more for meningiomas requiring brain surgery with lasting deficits. No global settlement existed as of 2026, and outcomes depend heavily on a pending general-causation fight and each plaintiff's injuries and duration of use.
A March 2024 study published in the BMJ found that prolonged use of medroxyprogesterone acetate — the active ingredient in Depo-Provera — was associated with a significantly increased risk of intracranial meningioma, a usually benign but potentially serious brain tumor. Plaintiffs also note that European and Canadian labels carried meningioma warnings the U.S. label allegedly lacked.
MDL 3140 is the federal Depo-Provera multidistrict litigation centralized in February 2025 before Judge M. Casey Rodgers in the U.S. District Court for the Northern District of Florida. It consolidates the meningioma cases for coordinated pretrial proceedings, including general-causation litigation and eventual bellwether trials, which will help set a framework for resolving the claims.
Generally, women who used Depo-Provera (or its generic, medroxyprogesterone acetate) — typically for an extended period — and were later diagnosed with an intracranial meningioma may qualify. Long-term use strengthens the claim under the BMJ study's findings. An attorney evaluates your medical records, duration of use, and timeline against the litigation criteria and your state's deadlines.
No — do not stop a prescribed contraceptive based on a lawsuit. Discuss any concerns with your doctor, who can review the latest information and discuss alternatives if appropriate. The litigation concerns a failure-to-warn allegation, not a directive for patients to discontinue treatment on their own.
Under IRS Publication 4345, compensatory damages for a physical injury or sickness such as a brain tumor are generally not taxable. Interest and punitive damages are taxable, and non-physical-injury portions may be treated differently. Confirm the treatment of any specific payout with a tax professional.
As of 2026, MDL 3140 was in early pretrial stages, litigating general causation and preparing for bellwether selection, with no jury trials yet. A settlement framework typically follows favorable causation rulings and bellwether verdicts. Mass-tort timelines often run several years, and this litigation's outcome is uncertain because causation is still being established.